ARWR
Price
$22.12
Change
+$0.25 (+1.14%)
Updated
Apr 26, 6:59 PM EST
10 days until earnings call
CANF
Price
$1.91
Change
-$0.04 (-2.05%)
Updated
Apr 26, 6:59 PM EST
Ad is loading...

ARWR vs CANF ᐉ Comparison: Which is Better to Invest?

Header iconARWR vs CANF Comparison
Open Charts ARWR vs CANFBanner chart's image
Arrowhead Pharmaceuticals
Price$22.12
Change+$0.25 (+1.14%)
Volume$353.25K
CapitalizationN/A
Can-Fite BioPharma
Price$1.91
Change-$0.04 (-2.05%)
Volume$1.4K
CapitalizationN/A
View a ticker or compare two or three
ARWR vs CANF Comparison Chart

Loading...

ARWRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CANFDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ARWR vs. CANF commentary
Apr 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Sell and CANF is a Sell.

COMPARISON
Comparison
Apr 28, 2024
Stock price -- (ARWR: $22.12 vs. CANF: $1.98)
Brand notoriety: ARWR: Notable vs. CANF: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 49% vs. CANF: 47%
Market capitalization -- ARWR: $2.74B vs. CANF: $10.3M
ARWR [@Biotechnology] is valued at $2.74B. CANF’s [@Biotechnology] market capitalization is $10.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $556.22B to $0. The average market capitalization across the [@Biotechnology] industry is $2.54B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileCANF’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • CANF’s FA Score: 1 green, 4 red.
According to our system of comparison, CANF is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 3 TA indicator(s) are bullish while CANF’s TA Score has 5 bullish TA indicator(s).

  • ARWR’s TA Score: 3 bullish, 5 bearish.
  • CANF’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CANF is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а -0.94% price change this week, while CANF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.69%. For the same industry, the average monthly price growth was -8.16%, and the average quarterly price growth was +1262.42%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 05, 2024.

CANF is expected to report earnings on Jun 01, 2023.

Industries' Descriptions

@Biotechnology (+1.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ARWR with price predictions.
OPEN
A.I.dvisor published
a Summary for CANF with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ARWR($2.74B) has a higher market cap than CANF($10.3M). CANF YTD gains are higher at: -10.000 vs. ARWR (-27.712).
ARWRCANFARWR / CANF
Capitalization2.74B10.3M26,612%
EBITDAN/AN/A-
Gain YTD-27.712-10.000277%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
ARWR vs CANF: Fundamental Ratings
ARWR
CANF
OUTLOOK RATING
1..100
5280
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
29
Undervalued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
8759
P/E GROWTH RATING
1..100
3100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (29) in the Biotechnology industry is significantly better than the same rating for ARWR (96). This means that CANF’s stock grew significantly faster than ARWR’s over the last 12 months.

ARWR's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as CANF (100). This means that ARWR’s stock grew similarly to CANF’s over the last 12 months.

ARWR's SMR Rating (98) in the Biotechnology industry is in the same range as CANF (98). This means that ARWR’s stock grew similarly to CANF’s over the last 12 months.

CANF's Price Growth Rating (59) in the Biotechnology industry is in the same range as ARWR (87). This means that CANF’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for CANF (100). This means that ARWR’s stock grew significantly faster than CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRCANF
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
ARWRDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CANFDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AFGGX17.250.10
+0.58%
Yorktown Growth A
FCGBX2.430.01
+0.41%
Templeton Global Balanced C
CIBCX66.910.12
+0.18%
American Funds Capital Income Bldr C
CCVAX30.750.05
+0.16%
Calvert Small-Cap A
NEJCX6.600.01
+0.15%
Natixis Vaughan Nelson Small Cap Value C

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with NTLA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
+1.14%
NTLA - ARWR
47%
Loosely correlated
+3.70%
ALNY - ARWR
46%
Loosely correlated
-0.28%
AXON - ARWR
46%
Loosely correlated
+0.65%
BEAM - ARWR
43%
Loosely correlated
-1.02%
INVA - ARWR
41%
Loosely correlated
+1.80%
More